What's Happening?
Bifrost Biosystems has entered into a commercial supply agreement with Illumina to integrate Illumina's sequencing-by-synthesis chemistry into its optical pooled screening (OPS) platform. This agreement is a crucial step towards the commercial deployment
of Bifrost's OPS technology, which links complex cellular phenotypes to genetic perturbations. The OPS platform is expected to be available commercially in early 2027, providing researchers with a scalable and cost-effective tool for functional genomics.
Why It's Important?
The agreement with Illumina represents a significant milestone for Bifrost Biosystems, as it validates the maturity of their OPS platform and enhances its commercial viability. By securing access to high-performance sequencing chemistry, Bifrost can offer a fully integrated solution that meets the needs of researchers in functional genomics. This development could democratize access to advanced genomic screening technologies, potentially accelerating discoveries in genetics and biotechnology.
What's Next?
Bifrost Biosystems is preparing for early-access deployments of its OPS platform to select research institutions and biotechnology companies. The integration of Illumina's sequencing chemistry is expected to enhance the platform's capabilities, making it a routine tool for biological discovery. As the platform becomes more widely available, it could lead to significant advancements in understanding genetic diseases and developing new therapies.
